Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors

• Published in: The FASEB journal 2011, Vol.25 (1), p.280-289
• Main Authors: van Lummel, Menno, van Blitterswijk, Wim J, Vink, Stefan R, Veldman, Robert Jan, van der Valk, Martin A, Schipper, Debby, Dicheva, Bilyana M, Eggermont, Alexander M.M, ten Hagen, Timo L.M, Verheij, Marcel, Koning, Gerben A
• Format: Article
• Language: English
• Subjects: Animals; Antibiotics, Antineoplastic - administration & dosage; Antibiotics, Antineoplastic - chemistry; Antibiotics, Antineoplastic - pharmacology; Cell Line, Tumor; cell membrane permeability; Cell Survival - drug effects; chemotherapy; Dose-Response Relationship, Drug; Doxorubicin - administration & dosage; Doxorubicin - chemistry; Doxorubicin - pharmacology; Drug Delivery Systems - methods; Glucosylceramides - chemistry; Humans; liposome; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; nanomedicine; Nanostructures - chemistry; Neoplasms - drug therapy; Neoplasms - pathology; short‐chain sphingolipid; Treatment Outcome; Unilamellar Liposomes - chemistry; Xenograft Model Antitumor Assays
• ISSN: 0892-6638; 1530-6860
• DOI: 10.1096/fj.10-163709

For amphiphilic anticancer drugs, such as the anthracyclin doxorubicin (Dox), uptake by tumor cells involves slow diffusion across the plasma membrane, a limiting factor in clinical oncology. Previously, we discovered that preinsertion of short-chain sphingolipids such as N-octanoyl-glucosylceramide (GC) in the tumor cell membrane enhances cellular Dox uptake. In the present study, we apply this strategy in vitro and in vivo by coadministering GC and Dox in a lipid nanovesicle (LNV). GC enrichment of Dox-LNVs strongly enhanced in vitro cytotoxicity toward B16 melanoma and A431 carcinoma, as evidenced by 6-fold decreased IC₅₀ values compared with Dox-LNVs. This correlated with enhanced cellular Dox uptake observed by confocal microscopy. Intravital optical imaging in window chamber-bearing mice with orthotopically implanted B16 melanoma demonstrated enhanced GC-mediated Dox delivery to tumor cells. Treatment of nude mice bearing human A431 xenografts with 6 mg/kg GC-Dox-LNVs almost doubled the tumor growth delay compared with Dox-LNVs. A second administration of 5 mg/kg after 3 d induced even 3-fold delay in tumor growth, while no systemic toxicity was found. GC-enriched Dox-LNVs displayed superior in vitro and in vivo antitumor activity, without systemic toxicity. This new drug delivery concept, aiming at increased membrane permeability for amphiphilic drugs, provides an opportunity to improve cancer chemotherapy.--Van Lummel, M., van Blitterswijk, W. J., Vink, S. R., Veldman, R. J., van der Valk, M. A., Schipper, D., Dicheva, B. M., Eggermont, A. M. M., ten Hagen, T. L. M., Verheij, M., Koning, G. A. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.